ENTRY       D10817                      Drug
NAME        Avelumab (USAN/INN);
            Avelumab (genetical recombination) (JAN);
            Bavencio (TN)
PRODUCT     BAVENCIO (EMD Serono)
SEQUENCE    (Heavy chain)
            EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYIMMWVRQA PGKGLEWVSS IYPSGGITFY
            ADTVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARIK LGTVTTVDYW GQGTLVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
            LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
            (Light chain)
            QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV
            SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTRV FGTGTKVTVL GQPKANPTVT
            LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
            YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
            (Disulfide bridge: H22-H96, H147-H203, H223-L215, H2229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'147-H'203, H'223-L'215, H'264-H'324, H'370-H'428, L22-L90, H138-L197, L'22-L'90, L'138-L'197)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FF04
            Product: D10817<JP/US>
EFFICACY    Antineoplastic, Immunomodulator, Anti-PD-L1 antibody
  DISEASE   Merkel cell carcinoma [DS:H01555]
            Urothelial carcinoma [DS:H00022]
            Renal cell carcinoma [DS:H00021]
  TYPE      Monoclonal antibody
TARGET      PDL1 (CD274) [HSA:29126] [KO:K06745]
  PATHWAY   hsa04514(29126)  Cell adhesion molecules
            hsa05235(29126)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF04 Avelumab
                  D10817  Avelumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Avelumab
                D10817  Avelumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10817  Avelumab (USAN/INN); Avelumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10817  Avelumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10817  Avelumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDL1 (CD274)
                 D10817  Avelumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10817
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10817
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10817
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10817
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10817
DBLINKS     CAS: 1537032-82-8
            PubChem: 319902617
///
